Impact of NexCAR 19
90%
Remission Rate
200+
Patients Treated
2x
Likely To Stay Cancer-free
2yrs
Longest Remission Rate
CAR-T Cell Therapy
Harnessing Your Immune System to Fight Cancer Safely
India faces a growing cancer burden, ranking second globally in cancer mortality. For aggressive B-cell malignancies like Acute Lymphoblastic Leukemia (blood cancer) and Large B-cell Lymphoma (lymph node cancer), over 40% of patients relapse or resist chemotherapy and other standard treatments.
ImmunoACT brings revolutionary CAR-T cell therapy for cancer treatment in India, where a patient’s own immune cells are genetically modified to recognize and destroy cancer cells. This groundbreaking approach has demonstrated remarkable improvements in overall survival and offers new hope for patients seeking advanced CAR-T therapy in India with limited treatment options.
Our Pipeline
Pioneering India's first indigenous CAR-T therapies, we are advancing innovative treatments to combat cancer with targeted, life-saving solutions.
Our Platform
Our proprietary technology platform enables efficient CAR-T cell production with in-house LV & plasmid manufacturing, giving us complete control over every aspect of creating an effective product.
NexCAR19: The Living Drug
NexCAR19, India's first approved CAR-T therapy, transforms patients' immune cells into living cancer-fighting agents, offering hope where conventional treatments fail.
Real Stories of Hope
At ImmunoACT, we believe that every patient story matters. Our CAR-T cell therapies are transforming lives-bringing hope where options were once limited. These powerful testimonials reflect not only the resilience of our patients but also the impact of cutting-edge, gene-modified cell therapy. As we work alongside leading healthcare institutions, academic collaborators, and strategic partners, our mission remains clear: to expand equitable access to advanced immunotherapies and redefine cancer care in India and beyond.
Our Manufacturing Facility
At ImmunoACT, our advanced manufacturing facility is purpose-built to deliver high-quality, safe, and scalable cell and gene therapies. With the capacity to treat up to 750 patients annually, we ensure timely and consistent access to life-saving treatments.
Built for Precision.
Designed for Patients.
Designed for Patients.
WHO-Certified GMP Facility
Global quality and safety standards ensuring purity, consistency, and efficacy in every therapy batch.
98% Manufacturing Success Rate
Industry-leading cell engineering success across all patient cohorts, minimising failures and therapy delays.
↑ 98% Manufacturing Success
Scalable Treatment Capacity
Expanding from 750 to 1,500 patients per year to meet growing demand and reduce treatment wait times.
↑ 1,500 Patients / Year
End-to-End Manufacturing
Fully integrated process from plasmid design to viral vector production and ex-vivo cell engineering.
Rapid and Reliable Delivery
Streamlined operations for fast turnaround, ensuring therapies reach patients when they need them most.
Global-Standard Quality Control
Dedicated QC/QA units rigorously test and validate each batch before release, meeting stringent benchmarks.
Clinician-Centric Support
Backed by experts in clinical trials, regulatory affairs, and treatment logistics to simplify doctor workflows.
Patient-Focused Outcomes
Every process is designed with one goal: enabling safe, accessible, and effective therapies for every patient.
Traceability and Audit Integrity
Robust chain-of-identity systems ensure full traceability from apheresis to infusion-ready product.
Partnered Hospitals
Our strong association with over 80 leading cancer treatment hospitals in India ensures hassle-free treatment with our CAR-T cell therapies.
Strategic Collaborations
To advance the research and development of our innovative gene-modified cell therapies, we are fostering relationships across academia, healthcare institutions, and strategic partnerships with the intent to equitize access.
Media
Cipla to take indigenously made CAR-T cell therapy from ImmunoAct to Africa
Business Line
20 Jan 2026Mango Sciences Announces Partnership With ImmunoACT to Bring the World’s First Bridge Financing Plan and Value-Based Offering for CAR-T Therapy for Cancer Patients in India
Business Wire
05 Dec 2025Indigenous CAR-T therapy signals new phase for India's cancer care and biotech manufacturing
The Economic Times
20 Feb 2026Publications
Read our publications, published in prestigious journals such as The Lancet Haematology, Molecular Cancer Therapeutics by AACR and Blood by the American Society of Hematology.
Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study
Article
Apr 24, 2025Blood Cancer Journal
Talicabtagene Autoleucel for Relapsed or Refractory B-cell Malignancies: Results from an Open-label, Multicentre, Phase 1/2 Study
Article
Apr 1, 2025The Lancent Haemotology
Excellent Safety Profile of a Low-Cost Novel Humanized CD19 CAR T-Cell Therapy, Actalycabtagene Autoleucel : Potential Impact on Access and Feasibility
Abstract
Dec 9, 2023American Society of Hematology Meeting
Stories of Hope
Ramnath Vishnu
Cancer Survivor
After years of setbacks with traditional treatments, CAR-T cell therapy changed everything. The idea of using my own cells to fight the cancer gave me hope. Now, I’m in remission, and I feel like I’ve truly gotten my life back. I can finally look forward to the future without fear.
Ramnath Vishnu
Cancer Survivor
After years of setbacks with traditional treatments, CAR-T cell therapy changed everything. The idea of using my own cells to fight the cancer gave me hope. Now, I’m in remission, and I feel like I’ve truly gotten my life back. I can finally look forward to the future without fear.
Ramnath Vishnu
Cancer Survivor
After years of setbacks with traditional treatments, CAR-T cell therapy changed everything. The idea of using my own cells to fight the cancer gave me hope. Now, I’m in remission, and I feel like I’ve truly gotten my life back. I can finally look forward to the future without fear.
Stories of Hope
Ramnath Vishnu
Cancer Survivor
After years of setbacks with traditional treatments, CAR-T cell therapy changed everything. The idea of using my own cells to fight the cancer gave me hope. Now, I'm in remission, and I feel like I've truly gotten my life back. I can finally look forward to the future without fear.
Sarah Mitchell
Cancer Survivor
The personalized approach of CAR-T therapy made all the difference. When conventional treatments weren't working, this innovative treatment gave me a second chance at life. Today, I'm cancer-free and grateful for every moment.
David Kumar
Cancer Survivor
I had almost given up hope until I learned about CAR-T cell therapy. The journey wasn't easy, but the results were worth it. Now I'm back to living life to the fullest, surrounded by my loved ones.
Real Stories of Hope
Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…
Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…
Ramnath Vishnu
Cancer Survivor
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Integer leo enim, fringilla sit amet massa vitae, faucibus consectetur neque…
Frequently Asked Questions
What is Leukapheresis and how does NexCAR19 involve it?
This is the process by which a patient's immune-effector cells are extracted through a machine. A bag of these extracted cells is transported under refrigerated conditions to ImmunoACT. From these, At our facility, we select and activate T-cells on which we manufacture NexCAR19. To be delivered for infusion to the patient.
Why does it take a few weeks for NexCAR19 to be administered?
NexCAR19 is made from a patient's own T-cells. The cells are sent to our controlled laboratory, cultured, modified, and then multiplied to reach a desirable dose. This takes ~19 days from Leukapheresis.
How many days after the therapy would CRS be expected?
Cytokine Release Syndrome (CRS) is the most frequent after-effect of the therapy, but it is expected within the first 4 weeks of the infusion, not long term.
How common are the serious side effects?
In our clinical trials, severe symptoms were seen in ~5% of patients. These side effects may depend upon several factors, including the pre-existing disease burden and your clinical condition.
Harnessing Your Immune System to Fight Cancer Safely
Begin Your Personalized Cancer Treatment Journey
